HbA1c — research review 2

...and this is where looking at human evidence, especially from clinical trials, really cuts through the noise. Take HbA1c, for instance.

Right, the three-month average of blood glucose, a common biomarker. There's a lot of talk about supplements and interventions lowering it, but what does the human data actually say?

Well, a lot of the initial excitement often comes from preclinical studies – cell cultures or animal models. But human physiology is far more complex. We need to see if those promising lab results translate to people.

And often, they don't. Or the effect size is much smaller than expected. We see this with many compounds touted for "anti-aging" or metabolic health. The robust, large-scale human trials are the gold standard.

Exactly. For example, a meta-analysis published in Diabetes Care in 2021 reviewed numerous trials on a particular supplement often marketed for glucose control. While some small studies showed minor shifts, the overall conclusion was that there wasn't consistent, statistically significant evidence for a meaningful reduction in HbA1c in the general population or even in prediabetic individuals.

So, a null result, or close to it, despite the buzz. This highlights the importance of not just looking for any study, but robust ones. And acknowledging what we still don't know.

Absolutely. What's often missing are long-term outcome studies. We might see a short-term biomarker change, but does that translate to improved health outcomes over years? Reduced risk of specific age-related diseases? For many interventions, that data simply isn't there yet. It’s still unproven.

So, even if something does nudge HbA1c slightly, we don't necessarily know if that small change makes a clinical difference in the long run. It’s crucial to separate those two things.